Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.